Pfizer Inc. $PFE Shares Sold by International Assets Investment Management LLC

International Assets Investment Management LLC lowered its holdings in Pfizer Inc. (NYSE:PFE) by 33.9% in the 3rd quarter, Holdings Channel reports. The firm owned 108,185 shares of the biopharmaceutical company’s stock after selling 55,504 shares during the period. International Assets Investment Management LLC’s holdings in Pfizer were worth $3,085,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. TOWER TRUST & INVESTMENT Co boosted its position in shares of Pfizer by 1.9% during the third quarter. TOWER TRUST & INVESTMENT Co now owns 19,322 shares of the biopharmaceutical company’s stock valued at $551,000 after buying an additional 357 shares during the last quarter. Angeles Wealth Management LLC raised its position in Pfizer by 2.2% in the 2nd quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 358 shares during the last quarter. Manchester Financial Inc. raised its position in Pfizer by 2.9% in the 2nd quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 365 shares during the last quarter. Signature Equity Partners LLC lifted its stake in Pfizer by 22.9% during the 3rd quarter. Signature Equity Partners LLC now owns 2,067 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 385 shares during the period. Finally, Delta Financial Advisors LLC lifted its stake in Pfizer by 1.6% during the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after acquiring an additional 398 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

Shares of NYSE:PFE opened at $29.38 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.42 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $167.47 billion, a PE ratio of 41.97, a price-to-earnings-growth ratio of 1.94 and a beta of 0.31. The firm’s 50 day moving average price is $28.74 and its 200-day moving average price is $26.90. Pfizer Inc. has a twelve month low of $23.62 and a twelve month high of $31.44.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.13. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The company had revenue of $16.58 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same period in the previous year, the business posted $0.87 earnings per share. The firm’s quarterly revenue was down .4% compared to the same quarter last year. Equities research analysts expect that Pfizer Inc. will post 3.04 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 5.9%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is currently 245.71%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on PFE shares. Argus set a $40.00 price target on shares of Pfizer in a report on Wednesday. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Royal Bank Of Canada increased their price objective on shares of Pfizer from $25.00 to $28.00 and gave the company a “sector perform” rating in a research report on Wednesday. JPMorgan Chase & Co. raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 9th. Finally, UBS Group lifted their target price on shares of Pfizer from $27.00 to $30.00 and gave the stock a “neutral” rating in a research report on Wednesday. Six analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $30.39.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s third-quarter results beat analyst expectations, and the company raised its 2026 earnings outlook. Reports also highlighted momentum from newer products, although margin pressure remains a concern. Pfizer Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
• Positive Sentiment: Guggenheim reiterated a Buy view and raised its price target to $33 from $31, signaling potential upside in the analyst’s view. Pfizer Receives a Buy from Guggenheim
• Neutral Sentiment: Pfizer updated an ulcerative-colitis treatment-pattern study and advanced a Phase 3 RSV-vaccine study in high-risk children. The announcements describe ongoing research; no efficacy or safety results were provided in the summaries. Pfizer Advances Phase 3 RSV Vaccine Study
• Negative Sentiment: DZ Bank cut its rating on Pfizer from Buy to Hold, a less favorable view that may temper optimism from other analysts. Pfizer also lagged in a news report focused on Moderna’s earnings-driven gain, though that comparison is not a change in Pfizer’s fundamentals. DZ Bank recommendations Moderna Climbs as Pfizer Dips

About Pfizer